RESULTS	Compared to placebo , rosiglitazone treated patients had a higher ( mean + or - SD ) body weight ( 89 + or - 15 kg vs. 84 + or - 15 kg , P = 0.02 ) at the end of the study , mostly related to an increment in subcutaneous adipose tissue .\